These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.
Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.
Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.
ACAAI 2024 Sanofi | Regeneron | Oct 24, 2024 - Oct 28, 2024
Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.
